Company profile: Zavante
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical development of novel therapies to improve the outcomes of hospitalized patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Zavante
Revive Therapeutics
HQ: Canada
Website
- Description: Provider of therapeutics and diagnostics, including Bucillamine, an oral thiol-based drug being developed for COVID-19, long COVID, other infectious diseases, and rare inflammatory disorders; psilocybin-based therapeutics for mental illnesses and substance use disorders; CBD therapeutics for autoimmune hepatitis and transplant injury prevention; and a point-of-care lateral flow test for post-COVID-19 conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revive Therapeutics company profile →
Topaz Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical products for children's health, offering drugs to treat head lice, acne, and infections, as well as vaccines against childhood diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Topaz Pharmaceuticals company profile →
Enantigen
HQ: United States
Website
- Description: Provider of discovery, development, and commercialization of novel drugs for life-threatening infectious diseases, with a primary focus on oral therapeutics for the treatment of hepatitis; located at the Pennsylvania Biotechnology Center.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enantigen company profile →
Antabio
HQ: France
Website
- Description: Provider of novel antibacterial resistance-breakers for drug-resistant infections, developing stand-alone inhibitors of bacterial metalloenzymes to restore antibiotic activity against critical pathogens; products include MEM-ANT3310 (meropenem + ANT3310, a serine-beta-lactamase inhibitor; targets CRAB and CRE), ANT3273 (inhaled for Pseudomonas aeruginosa), and ANT2681 (metallo β-lactamase inhibitor + meropenem for NDM CRE).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antabio company profile →
IGeneX
HQ: United States
Website
- Description: Provider of diagnostic solutions for tick-borne diseases, offering culture enhanced PCR, PCR, serology, ImmunoBlots, and FISH tests for Lyme disease, Bartonella, Babesia, and tick-borne relapsing fever, plus tick testing for pathogen detection and training services; engaged in research and development of tests that accurately detect these pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IGeneX company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Zavante
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Zavante
2.2 - Growth funds investing in similar companies to Zavante
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Zavante
4.2 - Public trading comparable groups for Zavante
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →